Global AMD market set to more than double

The pharmaceutical market for age-related macular degeneration will be driven by the entry of longer-acting therapies, according to analysts at GlobalData

eyechart and pen
Getty/Shidlovski
The pharmaceutical market for age-related macular degeneration (AMD) is expected to more than double by 2028 according to analytics company, GlobalData, as gaps between treatment options narrow.

While the market was worth an estimated $8.6bn across nine markets in 2018, this is expected to grow to $18.7bn in 2028 at a compound annual growth rate of 8.1%, according to the report, Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028.

The growth in the market is expected be driven by the entry of longer-acting anti-angiogenic therapies as well as the launch of products for dry AMD and geographic atrophy (GA) – for which there are currently no approved therapies, the analysts suggested.

Commenting on the market, pharma analyst at GlobalData, Magdalene Crabbe, said: “The unmet needs in the AMD market are set to be addressed in the coming years, as frequent intravitreal injections to treat wet AMD have become burdensome for patients who live in rural areas or have mobility issues.”

The analysts suggested there are 11 Phase III pipeline products for AMD, with six of the candidates expected to generate sales of more than $1bn in 2028.

For wet AMD, the development of two drugs, faricimab and ranibizumab SR by Roche, are expected to be well-received due to a low frequency of administration. The analysts predict this will contribute to projected sales of $16.3bn for wet AMB products in 2028.

Ms Crabbe explained that ranibizumab is formulated as an ocular implant and is expected to be changed approximately once a year, while faricimab is administered at intervals of 12-13 weeks. She commented that this gives the drugs a “favourable clinical profile” in comparison to standard-of-care therapies with shorter intervals.

GlobalData also identified four late-stage pipeline agents in the field of Dry AMD and GA. The analysts particularly highlighted MacuCLEAR’s antihypertensive agent MC-1101, which was given fast track designation by the FDA, and which is expected to launch in the US market and generate sales of $1.4bn in 2028.

The analysts also highlighted Novartis’ Beovu (brolucizumab), a monoclonal antibody therapy, which is expected to reach global sales of $3.6bn in 2028.

“Although the gaps between treatment options for wet AMD, dry AMD and geographic atrophy are narrowing, it is important to remember that many patients with slower progressing forms of AMD can remain undetected as the condition can be asymptomatic for a long period of time,” Ms Crabbe said, emphasising the importance of frequent eye examinations in order to benefit from the therapies entering the market in the years ahead.